Silex Systems (SLX) Investor Presentation summary

Investment highlights and strategic positioning

• Advancing commercialisation of third-generation SILEX laser enrichment technology, classified by US and Australian governments.

• Benefiting from global nuclear energy growth, US policy support, and industry moves toward a nuclear renaissance.

• Joint venture with Cameco (GLE) provides access to large US uranium tails inventories for up to 30 years.

• Key technology demonstration (TRL-6) underway, with potential for significant US government funding.

• Additional growth from quantum silicon for computing and medical isotope enrichment.

GLE commercialisation and market opportunity

• GLE is a US-based JV (Silex 51%, Cameco 49%) focused on SILEX technology, with sites in North Carolina and Kentucky.

• Paducah Laser Enrichment Facility (PLEF) targets up to 5 million lbs/year uranium production for 30 years.

• Revenue potential includes uranium, conversion, and enrichment services, with expansion into LEU and HALEU markets.

• Silex holds a minimum 25% equity in GLE and perpetual royalty of 7–12% on enrichment revenues.

• Recent milestones: TRL-6 demonstration started, PLEF site acquired, and selection for US DOE funding programs.

Nuclear sector trends and supply chain dynamics

• Nuclear power is critical for net zero targets, with over 400 reactors worldwide and significant growth planned.

• US is the largest nuclear power producer, importing ~95% of uranium and ~70% of enriched uranium.

• GLE's PLEF could address US supply vulnerabilities, leveraging exclusive access to DOE tails inventories.

• Western supply chain faces risks from over-reliance on Russian nuclear fuel, prompting sanctions and market bifurcation.

• Uranium, conversion, and enrichment prices have risen sharply since 2022 due to supply concerns.